Jade Biosciences, Inc. (JBIO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Jade Biosciences reported revenue of $0. Net income was -$127.4M, or -$3.19 per diluted share. Operating activities generated -$94.7M of cash, leaving -$94.9M of free cash flow. At fiscal year end, Jade Biosciences held $349.8M in total assets against $17.3M in total liabilities, including $88.4M of cash and equivalents.
Open the full interactive Jade Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Jade Biosciences Key Stats
| Share Price | $13.42 |
|---|---|
| Market Cap | $819.3M |
| 52-Week Range | $8.95 – $26.85 |
| Shares Outstanding | 61.1 million (basic, 2026 Q2) |
Jade Biosciences Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$23.0M | -$53.2M | -$81.4M | -$74.6M | -$113.5M |
| Pre-Tax Income | -$23.0M | -$51.5M | -$75.5M | -$69.6M | -$127.4M |
| Income Tax | $3,000 | $25,000 | $56,000 | $55,000 | $58,000 |
| Net Income | -$23.0M | -$51.5M | -$75.5M | -$69.6M | -$127.4M |
| Diluted EPS | -$65.45 | -$73.50 | -$100.45 | -$85.40 | -$3.19 |
Jade Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$25.2M | -$67.6M | -$40.4M | -$55.8M |
| Diluted EPS | -$0.48 | -$2.16 | -$0.57 | -$0.76 |
Jade Biosciences Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $54.2M | $22.4M | $23.5M | $33.8M | $88.4M |
| Current Assets | $174.3M | $131.5M | $124.2M | $80.1M | $348.8M |
| Total Assets | $175.4M | $135.3M | $127.4M | $80.3M | $349.8M |
| Current Liabilities | $2.5M | $7.8M | $17.6M | $3.8M | $16.5M |
| Total Liabilities | $2.9M | $8.6M | $18.0M | $3.9M | $17.3M |
| Shareholders' Equity | $172.4M | $126.7M | $109.5M | $76.4M | $332.5M |
Jade Biosciences Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$27.4M | -$39.1M | -$56.8M | -$71.2M | -$94.7M |
| Cash From Investing | -$113.4M | $6.9M | $11.9M | $56.0M | -$247.0M |
| Cash From Financing | $190.5M | $396,000 | $46.0M | $25.4M | $360.8M |
| Free Cash Flow | -$27.6M | -$39.3M | -$56.9M | -$71.3M | -$94.9M |
Figures from Jade Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Jade Biosciences financials page for every line item.
Jade Biosciences Company Profile
| Ticker | JBIO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Waltham, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001798749 |
Frequently Asked Questions
What was Jade Biosciences' revenue in fiscal 2025?
Jade Biosciences (JBIO) reported revenue of $0 for fiscal 2025.
What is Jade Biosciences' annual revenue history?
Jade Biosciences' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Jade Biosciences' net income in fiscal 2025?
Jade Biosciences reported net income of -$127.4M for fiscal 2025.
What was Jade Biosciences' earnings per share (EPS) in fiscal 2025?
Jade Biosciences' diluted EPS was -$3.19 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Jade Biosciences generate in fiscal 2025?
Jade Biosciences generated -$94.9M of free cash flow in fiscal 2025.
What was Jade Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Jade Biosciences reported revenue of $0.
How many shares of Jade Biosciences are outstanding?
Jade Biosciences reported a weighted average of 61.1 million basic shares outstanding in 2026 Q2.
What is Jade Biosciences' market cap?
Based on its latest closing price, Jade Biosciences (JBIO) has a market capitalization of about $819.3M.
When does Jade Biosciences' fiscal year end?
Jade Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Jade Biosciences headquartered?
Jade Biosciences lists its business address in Waltham, Massachusetts in its SEC filings.